Clinical trials: Hepatitis C Chronic
Hepatitis C Virus
Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection
This study is to evaluate the safety, tolerability, and antiviral activity of sofosbuvir (SOF) with ribavirin (RBV) in Egyptian adults with chronic genotype 4 hepatitis C virus (HCV) infection.
- Trial name
- NCT01713283
- Testing
- SOF, RBV
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
This prospective observational study will evaluate the efficacy and safety of two approved pegylated interferon-based direct acting antiviral triple therapies in patients with chronic hepatitis C genotype 1.
- Trial name
- NCT01508130
- Where
- 66 sites in United States, Puerto Rico
- Volunteers
- 672 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection
The purpose of this open-label study is to assess the safety, tolerability, antiviral activity, genotype resistance associated with virological failure, pharmacokinetics and pharmacodynamics of two dose regimens of miravirsen in…
- Trial name
- NCT01872936
- Testing
- Miravirsen, Telaprevir, Ribavirin
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 20 people
- Sponsor
- Santaris Pharma A/S
Hepatitis C
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
The objective of this trial is to collect evidence for the safety and efficacy of 24 weeks of treatment with BI 201335 240 mg in combination with 24 or 48 weeks of Pegylated Interferon (PegIFN) and ribavirin (RBV) in treatment…
- Trial name
- NCT01330316
- Testing
- BI 201335, PegIFN/RBV
- Where
- 87 sites in United States, Austria and 13 more
- Volunteers
- 119 people
- Sponsor
- Boehringer Ingelheim
Hepatitis C Virus
Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
The purpose of this study is to evaluate the efficacy of 6 or 8 weeks of treatment regimen containing simeprevir (SMV), daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naive (not having received treatment with any approved or…
- Trial name
- ACCORDION-1 (NCT02349048)
- Testing
- Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg
- Where
- 8 sites in United States, Canada
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
Hepatitis C, Chronic
Gilead Sustained Virologic Response (SVR) Registry
This Registry is designed to provide long term clinical and virologic follow up in participants who have achieved sustained virologic response (SVR) while participating in a previous Gilead sponsored hepatitis C virus (HCV)…
- Trial name
- NCT01457755
- Where
- 325 sites in United States, Australia and 15 more
- Volunteers
- 6,625 people
- Sponsor
- Gilead Sciences
Hepatitis C
Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients
Chronic active hepatitis C viral infections are difficult to treat: current drug therapies can result in severe side effects that some patients will not tolerate.
- Trial name
- NCT00229749
- Testing
- AVI-4065 Injection
- Volunteers
- 80 people
- Sponsor
- Sarepta Therapeutics, Inc.
HCV Infection
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection
The purpose of this study was to investigate the safety, tolerability, pharmacokinetics (PK), and antiviral activity of multiple doses of ACH-0137171 in participants with chronic hepatitis C virus (HCV) infection.
- Trial name
- NCT00401947
- Testing
- ACH-0137171
- Where
- 9 sites in United States, Germany and 1 more
- Volunteers
- 30 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hepatitis C, Chronic
PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)
This observational study will assess predictors of early on-treatment and sustained virological response in treatment-naïve patients with chronic hepatitis C initiated on treatment with Pegasys (peginterferon alfa-2a) and…
- Trial name
- NCT01070550
- Testing
- Peginterferon alfa-2a (Pegasys®)
- Where
- 266 sites in Austria, Brazil and 12 more
- Volunteers
- 4,680 people
- Sponsor
- Hoffmann-La Roche
Liver Transplantation, Hepatitis C, Chronic
Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)
This is an exploratory study and is a Phase 3, single-arm, multi-center, open-label study of pegylated interferon alfa-2b, PEG-IFN alpha-2b (PEG-Intron) and ribavirin (RBV) to determine the sustained virologic response (SVR) at…
- Conditions
- Liver Transplantation, Hepatitis C, Chronic, Liver Cirrhosis
- Trial name
- NCT00378599
- Testing
- Combination of (a) pegylated interferon alfa-2b and (b) rebetol
- Volunteers
- 125 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
This Registry is designed to obtain long term data on participants who have failed to achieve sustained virologic response (SVR) while receiving at least one Gilead oral antiviral agent (OAV) in a previous Gilead-sponsored…
- Trial name
- NCT01457768
- Where
- 323 sites in United States, Australia and 14 more
- Volunteers
- 570 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus
Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin
The purpose of this study is to identify one or more doses of BMS-650032 that, when used in combination with pegylated-interferon alpha and ribavirin are safe and demonstrate sufficient activity against hepatitis C virus…
- Trial name
- NCT01030432
- Testing
- BMS-650032, Peginterferon Alfa-2a, Ribavirin
- Where
- 40 sites in United States, Argentina and 6 more
- Volunteers
- 285 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
Study of a Novel Therapeutic Vaccine Against Hepatitis C Using Ad6NSmut and MVA-NSmut in Chronically Infected Patients
The purpose of this study is to determine whether administration of recombinant IMPs Ad6NSmut and MVA-NSmut (experimental vaccines for hepatitis C) in HCV chronically infected patients in combination with the standard…
- Trial name
- HCV004 (NCT01701336)
- Testing
- Ad6NSmut, MVA-NSmut
- Where
- 2 sites in Italy
- Volunteers
- 9 people
- Sponsor
- ReiThera Srl
Hepatitis C, Chronic
A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy
The purpose of this study is to evaluate the efficacy and safety of TMC435 in combination with peginterferon alfa-2a (PegIFNα-2a) and ribavirin in genotype 1 hepatitis C virus (HCV)-infected participants who failed to respond to…
- Trial name
- NCT01288209
- Testing
- TMC435, Peginterferon alfa-2a (PegIFNα-2a ), Ribavirin (RBV)
- Where
- 19 sites in Japan
- Volunteers
- 106 people
- Sponsor
- Janssen Pharmaceutical K.K.
Hepatitis C, Chronic
ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
This study will evaluate the efficacy and safety of different durations of treatment with PEGASYS combined with ribavirin in patients with CHC genotype 2 or 3 infection who have never previously received interferon (IFN) therapy.
- Trial name
- NCT00077636
- Testing
- Copegus, peginterferon alfa-2a [Pegasys]
- Where
- 132 sites in United States, Australia and 7 more
- Volunteers
- 1,469 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C Virus
Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2
The main objective of this study is to evaluate the safety and effectiveness of paritaprevir/ritonavir/ombitasvir with ribavirin used for participants infected with chronic hepatitis C virus (HCV) genotype 2 in daily practice in…
- Trial name
- NCT02945228
- Where
- 170 sites in Japan
- Volunteers
- 449 people
- Sponsor
- AbbVie
Hepatitis C, Chronic, Substance Abuse, Intravenous
Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261)
Previous intravenous drug abusers with chronic hepatitis C who are under substitution therapy (buprenorphine, methadone) will be treated with PegIntron and Rebetol according to the approved European labeling.
- Trial name
- SUPPORT (NCT00726557)
- Testing
- PegIntron (pegylated interferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 246 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C Infection
Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382
The purpose of this study is to determine the safety, tolerability, pharmacokinetics (what the body does to the medication) and antiviral activity of JNJ-47910382 when administered in different dosing regimens in Caucasian…
- Trial name
- NCT01651767
- Testing
- JNJ-47910382
- Where
- 6 sites in Germany
- Volunteers
- 11 people
- Sponsor
- Janssen R&D Ireland
Chronic Hepatitis C
CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) Subjects
To explore the effect on early viral kinetics and viral load, and to determine safety, tolerability and anti-viral response for the plasmid DNA vaccine CHRONVAC-C administered i.m.
- Trial name
- NCT01335711
- Testing
- ChronVac-C + SOC, SOC
- Where
- 2 sites in Sweden
- Volunteers
- 32 people
- Sponsor
- ChronTech Pharma AB
Hepatitis C
Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection
1. Evaluate the safety, tolerability, and virologic activity of escalating single (and multiple) doses of XTL6865, a mixture (1:1) of two human monoclonal antibodies (HCV-AbXTL68 and HCV-AbXTL65), in patients with chronic…
- Trial name
- NCT00300807
- Testing
- XTL 6865
- Where
- 5 sites in United States, Israel
- Volunteers
- 36 people
- Sponsor
- XTL Biopharmaceuticals